U.S. FDA Removes Clinical Hold on CEL-SCI’s Phase 3 Head & Neck Cancer Trial

(August 21, 2017)

CEL-SCI Corporation today announced it has received a letter from the U.S. Food and Drug Administration (FDA) stating that the clinical hold that had been imposed on the Company’s Phase 3 cancer study with Multikine* (Leukocyte Interleukin, Inj.) has... Continue Reading


Head and Neck Cancer-What You Need to Know

(August 14, 2017)

Head and neck cancer includes a number of different malignant cancers that develop in or around the throat, larynx (voice box), nose, sinuses and mouth. Globally, head and neck cancer is the seventh most common type of cancer with an estimated 400,000-600,000... Continue Reading


Targeted radiotherapy for head and neck cancer could reduce the risk of dry mouth

(February 22, 2017)

A troublesome side effect of radiation therapy treatment of cancers involving the head and neck is dry mouth.  This occurs as a consequence of radiation damage to the salivary glands.  According to a new study, changing the intensity of radiotherapy... Continue Reading


Nearly half of U.S. men actively infected with HPV, study finds HPV-linked cancers on the rise in men, but nearly 9 in 10 vaccine-eligible men are unvaccinated!

(February 20, 2017)

By Rachel Tompa / Fred Hutch News Service The most common sexually transmitted infection in the U.S. has a bit of a twist. It’s what’s known as a “subclinical infection” — those infected suffer no immediate consequences, but years later have... Continue Reading


Twice-daily radiation therapy reduces mortality from head and neck cancer

(February 14, 2017)

Treating head and neck cancer patients with a twice-daily radiation therapy schedule combined with chemotherapy could save more lives, according to new research presented at the European Cancer Congress 2017.1 Around 600,000 people are diagnosed with... Continue Reading


Opdivo Approved for Advanced Head and Neck Cancer

(November 28, 2016)

The United States Food and Drug Administration (FDA) has approved the immunotherapeutic agent, Opdivo® (nivolumab) for the treatment of advanced head and neck cancer. Specifically,  the indication is for the treatment of squamous cell carcinoma of the... Continue Reading


PET/CT Combined More Effective Than MRI in Monitoring Head and Neck Cancer Patients’ Response to Treatment

(October 5, 2016)

According to a recent study, combining PET/CT to monitor response to treatment in head and neck cancer patients appears more effective than MRI. Using PET/CT may better inform doctors whether treatment for head and neck cancer is working after just one... Continue Reading


Keytruda® Approved for Advanced Head and Neck Cancer

(September 7, 2016)

The United States Food and Drug Administration (FDA) has approved Keytruda® (pembrolizumab) for the treatment of advanced head and neck cancer that has stopped responding to platinum-based chemotherapy agents.1 Globally, head and neck cancer comprises... Continue Reading


Compliance with Radiation Schedules Improves Survival in Head and Neck Cancer

(June 9, 2016)

Patients with head and neck cancer who comply with their scheduled radiation treatments have significantly improved outcomes compared to those who miss 2 or more of their appointments within the prescribed time period. These results were recently published... Continue Reading


Long-Lasting Responses Achieved with Keytruda® in Advanced Head and Neck Cancer

(June 8, 2016)

Treatment with the immune-stimulating agent, Keytruda® (pembrolizumab), provides impressive long-term outcomes for some patients with metastatic or recurrent head and neck cancer. These results were recently presented at the 2016 annual meeting of the... Continue Reading


Latest Head and Neck Cancer News By Stage


General Head and Neck Cancer

Twice-daily radiation therapy reduces mortality from head and neck cancer

(February 14, 2017)

Treating head and neck cancer patients with a twice-daily radiation therapy schedule combined with chemotherapy could save more lives, according to new research presented at the European Cancer Congress 2017.1 Around 600,000 people are diagnosed with... Continue Reading


Opdivo Approved for Advanced Head and Neck Cancer

(November 28, 2016)

The United States Food and Drug Administration (FDA) has approved the immunotherapeutic agent, Opdivo® (nivolumab) for the treatment of advanced head and neck cancer. Specifically,  the indication is for the treatment of squamous cell carcinoma of the... Continue Reading


PET/CT Combined More Effective Than MRI in Monitoring Head and Neck Cancer Patients’ Response to Treatment

(October 5, 2016)

According to a recent study, combining PET/CT to monitor response to treatment in head and neck cancer patients appears more effective than MRI. Using PET/CT may better inform doctors whether treatment for head and neck cancer is working after just one... Continue Reading


Keytruda® Approved for Advanced Head and Neck Cancer

(September 7, 2016)

The United States Food and Drug Administration (FDA) has approved Keytruda® (pembrolizumab) for the treatment of advanced head and neck cancer that has stopped responding to platinum-based chemotherapy agents.1 Globally, head and neck cancer comprises... Continue Reading


Compliance with Radiation Schedules Improves Survival in Head and Neck Cancer

(June 9, 2016)

Patients with head and neck cancer who comply with their scheduled radiation treatments have significantly improved outcomes compared to those who miss 2 or more of their appointments within the prescribed time period. These results were recently published... Continue Reading


More General Head and Neck Cancer